07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting the MLXIP / TXNIP / ARRDC4 pathway could help treat obesity. In cultured human skeletal myotubes, siRNA targeting MLXIP or a MLXIP inhibitor tool...
08:00 , Jan 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MLX interacting protein-like (MLXIPL; CHREBP) Studies in cell culture and in mice suggest that inhibiting CHREBP could help treat cancer. In a human colorectal...
07:00 , Oct 22, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Markers for response to peroxisome proliferation-activated receptor-g (PPARG; PPARg) agonist therapy in insulin-resistant patients A gene expression study in human subjects identified markers that could help...